



PRESS RELEASE

Published: 2025-05-22

Inhalation Sciences Signs Strategic Agreement with U.S.-based BioLum Sciences, expanding U.S. Presence & Commercial Reach to Advance In Vitro Respiratory Research

Stockholm, May 22, 2025 - Inhalation Sciences AB (ISAB) today announces that the company has entered into a Master Service Agreement (MSA) with the US-based company BioLum Sciences, active in inhalation research and diagnostics. The collaboration aims to strengthen ISAB's commercial presence in the US, increase the availability of the company's technologies and meet the growing demand for advanced in vitro models in line with new regulatory guidelines from the FDA.

BioLum Sciences, based in Dallas, Texas, is an innovative company specializing in the development of novel inhalation diagnostic platforms and oxidative biomarker technologies. Through this collaboration, ISAB's advanced technologies - **PreciseInhale®** and **DissolvIt®** - will become more accessible to U.S.-based researchers and drug development clients, enhancing support for preclinical respiratory research and regulatory-aligned development.

The FDA's recently published guidelines for in vitro methods, as well as the fact that the company's in vitro model DissolvIt® was used in a recently completed FDA regulatory study, have led to increased attention and demand for ISAB's technology. This partnership is a strategic step in capitalizing on this demand.

Manoush Masarrat, CEO Inhalation Sciences, comments:

"We see this collaboration as an important step in our expansion in the US. BioLum Sciences shares our vision of replacing animal studies with more precise and ethically defensible methods. With their strong network and scientific expertise, we will be able to meet the increasing demand from US customers who are now adapting to the new FDA guidelines."

Jack Reynolds, CEO of BioLum Sciences, adds:

"We are delighted to be working with Inhalation Sciences. Their technology is cutting edge, and the demand for sophisticated in vitro models is growing rapidly in the U.S. This partnership allows us to address a critical need in respiratory research and together, we will expand preclinical capabilities and offer customers a powerful combination of scientific expertise, advanced technology, and regulatory insight - to accelerate discovery and development."

The new collaboration strengthens ISAB's strategic presence in one of its key growth markets and marks an increased focus on commercial development in line with the company's long-term strategy.

For more information, please contact:

Manoush Masarrat, CEO
Mobile: +46 (0)73 628 9153
E-mail: manoush.masarrat@inhalation.se

Jack Reynolds, CEO
Mobile: (720) 985-3131
E-mail: jpreynolds@biolumsciences.com

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

About BioLum Sciences

BioLum Sciences is a U.S.-based integrated CRO developing advanced diagnostic technologies for real-time measurement of oxidative stress markers, supporting research and clinical development in respiratory, cardiovascular, and other inflammation-driven diseases. BioLum delivers high-sensitivity tools in both early discovery and translational research.